1. Home
  2. PETS vs ACRS Comparison

PETS vs ACRS Comparison

Compare PETS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PetMed Express Inc.

PETS

PetMed Express Inc.

HOLD

Current Price

$2.00

Market Cap

38.0M

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.47

Market Cap

608.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PETS
ACRS
Founded
1996
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.0M
608.9M
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
PETS
ACRS
Price
$2.00
$5.47
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$10.20
AVG Volume (30 Days)
785.2K
1.9M
Earning Date
06-09-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.01
EPS
N/A
N/A
Revenue
$273,800,000.00
$1,683,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.98
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$1.46
52 Week High
$4.10
$5.69

Technical Indicators

Market Signals
Indicator
PETS
ACRS
Relative Strength Index (RSI) 55.32 73.35
Support Level $1.62 $4.13
Resistance Level $2.41 N/A
Average True Range (ATR) 0.12 0.29
MACD 0.04 0.10
Stochastic Oscillator 43.08 91.00

Price Performance

Historical Comparison
PETS
ACRS

About PETS PetMed Express Inc.

PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: